BioCatalystWatch
ABBVWorkspace / ABBV / OverviewCompany library
Price
Market cap
Next catalystExpected 2026Rinvoq (upadacitinib) · Phase 3 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

Elahere + bevacizumab — GLORIOSA

FRα

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

BCMA × CD3

Upcoming / outlook

  • Timing and evidence

IL-1α × IL-1β

Upcoming / outlook

  • Timing and evidence

CD3 × CD20

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Epcoritamab + lenalidomide — EPCORE DLBCL-4

CD3 × CD20

PreINDP1P2P3FilingApproved
Upcoming / outlook

ABBV-400

c-Met

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

UBRELVY (ubrogepant)

CGRP receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

ABBV-400

c-Met

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Qulipta (atogepant)

CGRP receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

UBRELVY (ubrogepant)

CGRP receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Qulipta (atogepant)

CGRP receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Other pipelines

ABBV-181

PD-1

PreINDP1P2P3FilingApproved

SEZ6

PreINDP1P2P3FilingApproved
ABBV-151

GARP–TGF-β1

PreINDP1P2P3FilingApproved

Partner / License out

VEGF

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

VEGF

CD19

Approved / commercial

c-Met

Approved

PreINDP1P2P3FilingApproved

History / paused

Integrin β7 (α4β7 and αEβ7)

BCMA × CD3

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Dopamine D3 receptor × Dopamine D2 receptor × 5-HT1A receptor × 5-HT2A receptor × 5-HT2B receptor × Histamine H1 receptor × 5-HT2C receptor × α1A-adrenergic receptor

Dopamine D3 receptor × Dopamine D2 receptor

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ABBV PR & News

PR & News

ABBV SEC archive